in vivo News and Research

RSS

Cardiac pacemaker could be powered by kinetic energy from the heart

The cardiac pacemaker of the future could be powered by the heart itself, according to researchers at Shanghai Jiao Tong University.

4 Aug 2021

Rigaku Acquires Life Science Imaging Equipment Manufacturer MILabs

Rigaku Corporation (Headquarters: Akishima-shi, Tokyo; President: Toshiyuki Ikeda; "Rigaku"), a leading manufacturer of X-ray analysis equipment, has acquired all issued shares of MILabs B.V. (Headquarters: Houten, The Netherlands; CEO and CSO: Dr. Frederik Beekman; “MILabs”)

From Rigaku Corporation 4 Aug 2021

Next-generation CRISPR tools and therapies improved by modified RNA guides

A new type of gene-editing tool, CRISPR-Cas13, has shown promise in RNA targeting. Previous studies have shown the tool as a potential treatment method for viral diseases, including coronavirus disease (COVID-19).

3 Aug 2021

Study shows COVID-19 organ-specific outcomes depend on anti-spike glycoprotein antibodies

A recent study from the University of Rochester reveals how the biodistribution kinetics and the affinity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for many different organs in the human body can be affected by antibodies targeting viral spike glycoprotein. The paper is currently available on the bioRxiv* preprint server while it undergoes peer review.

3 Aug 2021

“Sybodies” protect against SARS-CoV-2 in hamster model

Researchers in China, The Netherlands, France, and Switzerland have identified synthetic nanobodies or “sybodies” that exhibit potent neutralizing activity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers in the United States have described a novel antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being evaluated in clinical trials as a treatment for coronavirus disease 2019 (COVID-19).

2 Aug 2021

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

A pioneering study reports on the interaction of a tailored titanium oxide nanoparticle (NP) with the full-length SARS-CoV-2 non-structural protein 1 (nsp1). This should be of value in developing new therapeutic tools against coronaviruses that act by targeting their proteins. It could also help map the structure of activated proteins.

2 Aug 2021

Could novel biosensors facilitate SARS-CoV-2 antiviral drug research?

An intriguing new study presents a novel approach to biosensor-based evaluation of promising drugs that could inhibit the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via its 3C-like protease (3CLpro), a viral protease.

2 Aug 2021

Fighting SARS-CoV-2 with nanomedicine

Published in the Journal of Controlled Release, researchers from the German University in Cairo, and the University of Cologne, looked into nano-reformulation of repurposed antiviral and immune-modulating drugs for inhalation therapy against COVID-19. In addition, they focused on how nanomedicine could address the limitations of current therapeutics, enhancing the efficacy, specificity, and safety of such drugs.

1 Aug 2021

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Considering the antiviral activity of medicinal herbs, a new study published in the journal Current Pharmacology Reports focuses on the identification of potent phytochemicals from Himalayan herbs, namely, Rheum emodi, Thymus serpyllum, and Artemisia annua, for the treatment of COVID-19.

1 Aug 2021

Study paves the way to a new drug design concept

Hydrogen peroxide reacts with copper to produce hydroxyl radicals with strong antibacterial properties. However, this requires high copper concentrations because two copper atoms have to come close together, which occurs by chance.

31 Jul 2021

Researchers develop two complementary bladder models to study UTIs

Urinary tract infections (UTIs) are among the most common bacterial infections. They usually require treatment with antibiotics, and almost a quarter of treated cases lead to recurrent infection.

30 Jul 2021

Large nanodiscs simulate viral entry into host cells

In a paper recently uploaded to the journal Frontiers in Biotechnology by Padmanabha Das et al. (June 12th, 2020), a method of producing significantly larger homogenous nanodiscs up to 90 nm in diameter is described, and the advantages and applications of such nanodiscs are explored: better replicating the actual curvature and membrane symmetry of a real cell membrane, and allowing much larger or multiple membrane proteins to be loaded simultaneously.

30 Jul 2021

ICTER scientists improve the precision of cornea imaging using a non-invasive method

Until recently, researchers could mainly observe the eye cornea through a close microscope contact with living, or dead cells.

29 Jul 2021

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

A Korean study has recently demonstrated antiviral potency of monoclonal antibody CT-P59 against the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The experiments conducted in animals infected with the delta variant have shown that CT-P59 is able to reduce symptom intensity and viral replication in the respiratory tract. The study is currently available on the bioRxiv* preprint server.

27 Jul 2021

Variations in human ACE2 genetics associated with coronavirus susceptibility

In a recent study, the researchers sought to understand the genetic variability in ACE2 that may contribute to inconsistent clinical outcomes of COVID-19.

25 Jul 2021

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

A new study has been published on the bioRxiv* preprint server, which has identified and characterized two RBD-targeting neutralizing nanobodies, namely, DL4 and DL28.

23 Jul 2021

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Researchers in Canada have reported the discovery of a multi-antibody cocktail that synergistically protected against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an animal model of acute infection.

22 Jul 2021

Cell-analysis method could pave the way for new vaccine strategies against tuberculosis

A new method that analyzes how individual immune cells react to the bacteria that cause tuberculosis could pave the way for new vaccine strategies against this deadly disease, and provide insights into fighting other infectious diseases around the world.

22 Jul 2021

Researchers use nanoparticles as heaters to manipulate the electrical activity of neurons

Nanomaterials have been used in a variety of emerging applications, such as in targeted pharmaceuticals or to bolster other materials and products such as sensors and energy harvesting and storage devices.

22 Jul 2021